☆ 4.6 Letter

Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry

BRITISH JOURNAL OF DERMATOLOGY (2023)

Related references

Note: Only part of the references are listed.
Letter Dermatology

Dose spacing and reduction strategies in biotherapies for stable, clear or almost clear psoriasis: A survey of practices in France

H. Aubert et al.

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2022)

Add to Collection
Review Pharmacology & Pharmacy

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review

C. A. J. Michielsens et al.

Summary: Biologic tapering appears to be effective and safe in psoriasis patients with stable low disease activity or clinical remission. More research is needed to address the current gaps in knowledge, particularly in terms of tapering criteria and strategies, long-term safety, predictors for successful tapering, cost-effectiveness, and evaluation of newer generation biologics.

DRUGS (2021)

Add to Collection
Article Dermatology

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice

Selma Atalay et al.

Summary: The study found that a tightly controlled dose reduction strategy for adalimumab, etanercept, and ustekinumab in patients with psoriasis can safely decrease drug dosages and maintain the use of lower doses.

ACTA DERMATO-VENEREOLOGICA (2021)

Add to Collection
Article Dermatology

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis A Randomized Clinical Trial

Selma Atalay et al.

JAMA DERMATOLOGY (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.